CMPX (Compass Therapeutics) Market Value to Book Value Ratio

Compass Therapeutics' success in oncology relies on patent protection and FDA test results, which is confirmed by the current market value of 0.83 as reflected on the chart. Risks are minimized through the launch of multiple parallel combination therapy programs. Meanwhile, the modern network of research centers operates without equipment depreciation, ensuring full capacity utilization for antibody development.

This indicator measures the market premium over the net asset value, reflecting the level of investor confidence in capital management efficiency relative to its book valuation. For Compass Therapeutics (CMPX), the price-to-book ratio correlates with the success of antibody clinical trials, where an upward trend signals guaranteed future payments from pharma behemoths and the reliability of the asset.